|
著書・論文
|
- Yoshino Y, Chikashi I. Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells. Sci. Rep. 2015 vol. 5 13249
- Fujita H, Yoshino Y, Chiba N. Regulation of centrosome cycle. Mol. Cell. Oncol 2015 in press
- Yoshino Y, Suzuki M, Takahashi H, Ishioka C. Inhibition of invasion by glycogen synthase kinase-3 beta inhibitors through dysregulation of actin re-organisation via down-regulation of WAVE2. Biochem. Biophys. Res. Commun. 2015. Vol. 464, pp 275-280
- Yoshino Y, Akiyama S, Ouchi K, Oishi T, Takahashi H, Lee J, Takahashi S, Shimodaira H, Kato S, Ishioka C. Acute exacerbation of paraneoplastic neurological syndrome after massive tumor lysis of neuroendocrine carcinoma by chemoradiotherapy. Int. Cancer Conf. J. 2013. vol. 2, pp 247-250
- Sekine H, Chen N, Sato K, Saiki Y, Yoshino Y, Umetsu Y, Jin G, Nagase H, Gu Z, Fukushige S, Sunamura M, Horii A. S100A4, frequently overexpressed in various human cancers, accelerates cell motility in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2012. vol. 429, pp 214-219
- Saiki Y*, Yoshino Y*, Fujimura H*, Manabe T, Kudo Y, Shimada M, Mano N, Nakano T, Lee Y, Shimizu S, Oba S, Fujiwara S, Shimizu H, Chen N, Nezhad ZK, Jin G, Fukushige S, Sunamura M, Ishida M, Motoi F, Egawa S, Unno M, Horii A (* co-first author) DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem. Biophys. Res. Commun. 2012. vol. 421, pp 98-104
- Yoshino Y, Ishida M, Horii A. A new 10-min ligation method using a modified buffer system with a very low amount of T4 DNA ligase: the “Coffee Break Ligation” technique. Biotechnol. lett. 2007. vol. 29, pp 1557–60
- 吉野優樹、千葉奈津子. インフォームドコンセントのための図説シリーズ 抗悪性腫瘍薬-分子標的治療薬-改訂版 V. 分子標的治療薬を含む標準的治療 4)乳がん (in press)
- 吉野優樹、石岡千加史. 分子標的薬の耐性機序. がん分子標的治療、2014. vol. 12、pp 122-128
- 吉野優樹、石岡千加史. 分子標的治療薬の進歩 ~特徴と将来の展望~. 耳鼻咽喉科学会誌、2013. vol. 85、pp 472-478
- 吉野優樹、石岡千加史. 転移性肺腫瘍に対する分子標的治療・消化器癌. 日本胸部臨床、2013. vol. 73、pp 146-164
|
